Taking RNAi from interesting science to impactful new treatments
Alnylam Pharmaceuticals, founded by MIT professors and former postdocs, has turned the promise of RNAi research into a new class of powerful therapies.
Alnylam Pharmaceuticals, founded by MIT professors and former postdocs, has turned the promise of RNAi research into a new class of powerful therapies.
A microneedle patch that delivers immune-regulating molecules can teach T cells not to attack hair follicles, helping hair to regrow.
In a study of cells from nearly 400 ALS patients, researchers identified genomic regions with chemical modifications linked to disease progression.
Lydia Bourouiba’s research on fluid dynamics influenced new guidance from the World Health Organization that will shape how health agencies respond to respiratory infectious diseases.
Immunai’s founders were researchers at MIT when they launched their company to help predict how patients will respond to new treatments.
MIT spinout Strand Therapeutics has developed a new class of mRNA molecules that can sense where they are in the body, for more targeted and powerful treatments.
Single-cell gene expression patterns in the brain, and evidence from follow-up experiments, reveal many shared cellular and molecular similarities that could be targeted for potential treatment.
Researchers also found that a variant of the protein is not as protective against the bacteria and increases susceptibility to the disease.
Study finds stimulating a key brain rhythm with light and sound increases peptide release from interneurons, driving clearance of an Alzheimer’s protein.
Professor Ernest Fraenkel has decoded fundamental aspects of Huntington’s disease and glioblastoma, and is now using computation to better understand amyotrophic lateral sclerosis.
Stimulating gamma brain waves may protect cancer patients from memory impairment and other cognitive effects of chemotherapy.
Albert Almada PhD ’13 studies the mechanics of how stem cells rebuild tissues. “Digging deep into the science is what MIT taught me,” he says.
Performing this test could help doctors prevent dysfunction that can occur when the right and left ventricles of the heart become imbalanced.
Biologists demonstrate that HIV-1 capsid acts like a Trojan horse to pass viral cargo across the nuclear pore.
A compound originally developed to treat cancer could be repurposed to treat polycystic kidney disease, an inherited condition that can lead to kidney failure.